 | |
| Company type | Public |
|---|---|
| Traded as |
|
| Industry | synthetic biology |
| Founded | 2013; 11 years ago (2013) |
| Founders |
|
| Headquarters | South San Francisco, California |
| Products | Genes and gene fragments, NGS products |
| Revenue |  $54.2 million(2019) |
| Number of employees | 400 |
| Website | twistbioscience |
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
The company was represented by Leproust at a March 2021 tabletop exercise at the Munich Security Conference simulating an outbreak of weaponized monkeypox.
In May 2021, Twist Bioscience and Genome Project-Write launched a new CAD platform for whole genome design. The CAD will automate workflows to enable collaborative efforts critical for scale-up from designing plasmids to megabases across entire genomes.
References
- "Twist Bioscience | Twist Bioscience Reports Fourth Quarter and Full Year Fiscal 2019 Financial Results". investors.twistbioscience.com.
- Strickland, Eliza (December 23, 2015). "DNA Manufacturing Enters the Age of Mass Production". IEEE Spectrum: Technology, Engineering, and Science News.
- Yassif, Jaime; O'Prey, Kevin; Isaac, Christopher (November 2021). "Strengthening Global Systems to Prevent and Respond to High-Consequence Biological Threats" (PDF). Nuclear Threat Initiative. Archived (PDF) from the original on 2022-07-09. Retrieved 2022-07-09.
- "CAD Platform Developed by GP-Write and Twist to Launch Large Genome Projects". Genetic Engineering & Technology News. May 12, 2021.